awmsg logo



misoprostol (Mysodelle®)


Reference No. 3627

Publication date:
23/03/2018


Appraisal information

misoprostol (Mysodelle®) 200 microgram vaginal delivery system


Company: Ferring Pharmaceuticals (UK)
BNF category: Obstetrics, gynaecology, and urinary-tract disorders
NMG meeting date: 07/02/2018
AWMSG meeting date: 14/03/2018
   
   
Submission Type: Resubmission
Status: Recommended
Advice No: 0618
Ratification by Welsh Government: 22/03/2018

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

Misoprostol (Mysodelle®) is recommended as an option for use within NHS Wales for the induction of labour in women with an unfavourable cervix, from 36 weeks gestation, in whom induction is clinically indicated.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download